Notably, bioluminescent imaging showed that silencing NETO2 promoted glioma growth (Fig. 5f), and immunohistochemical analysis confirmed that NETO2 was significantly downregulated in glioma allografts co-implanting GL261-LRIG3 and TAM-shNETO2 (Fig. 5g). The gene discussed is NETO2; the disease is central nervous system cancer.